Trial Profile
A Multicenter, Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 2 Clinical Trial to Evaluate the Efficacy in Reduction of Intraocular Pressure and Safety of PHP-201 in Patients With Normal Tension Glaucoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2022
Price :
$35
*
At a glance
- Drugs PHP 201 (Primary)
- Indications Low tension glaucoma
- Focus Therapeutic Use
- Sponsors pH Pharma
- 01 Mar 2022 Primary endpoint has been met (Mean diurnal IOP change from baseline at post-treatment time point of 4 weeks- PHP-201 0.5%), as per Results published in the Acta Ophthalmologica
- 01 Mar 2022 Primary endpoint has been met (Mean diurnal IOP change from baseline at post-treatment time point of 4 weeks - PHP-201 0.25%), as per Results published in the Acta Ophthalmologica
- 01 Mar 2022 Results published in the Acta Ophthalmologica